Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines to Participate in Upcoming Investor Conferences

June 08, 2023 | Last Trade: US$35.96 0.63 1.78

REDWOOD CITY, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Goldman Sachs 44^th Annual Global Healthcare Conference and in Barclays’ ongoing series of virtual lunchtime fireside chats.

Details of the company’s participation are as follows:

Goldman Sachs 44^th Annual Global Healthcare Conference
Conference Dates: June 12-15, 2023
Fireside Chat Time/Date: 11:40 a.m. Eastern on Wednesday, June 14, 2023
Location: Dana Point, California; webcast available

Barclays Virtual Fireside Chat Series
Fireside Chat Time/Date: 12:00 p.m. Eastern on Thursday, June 15, 2023
Location: Virtual; webcast available

To access the live webcasts of the Goldman Sachs and Barclays fireside chats, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of each webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RAS^MULTI) and RMC-6291(KRAS^G12C) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRAS^G12D) and RMC-0708 (KRAS^Q61H), both of which are currently in IND-enabling development, RMC-8839 (KRAS^G13C), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

Stock Quote

Last Trade:	US$35.96
Daily Change:	0.63 1.78
Daily Volume:	1,197,506
Market Cap:	US$5.920B

April 09, 2024 Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins April 08, 2024 Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins March 28, 2024 Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 February 26, 2024 Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress January 04, 2024 Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference LOAD MORE NEWS

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE